文献速递神经肌肉病

他达拉非治疗杜氏肌营养不良的3期随机安慰剂对照试验

A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
PubMed 文献 · Neurology · 2017-09-29

主要终点6分钟步行距离(6MWD)下降在组间无显著差异,次要终点亦无影响;仅在>10岁男孩中低剂量他达拉非组上肢功能(PUL)总分及肩部子评分下降较安慰剂组少。结论为他达拉非未能减缓步行能力下降。

要点

  • 他达拉非未减缓7–14岁DMD男孩48周6MWD下降。
  • 低剂量他达拉非在>10岁男孩中可能减少上肢功能下降。
  • 不良事件与他达拉非已知安全性及DMD疾病状态一致。

核心结论

  • 他达拉非未能减轻杜氏肌营养不良男孩步行能力的下降。

主要发现

  • 48周6MWD下降:安慰剂组51.0±9.3 m,低剂量他达拉非组64.7±9.8 m(vs 安慰剂 p=0.307),高剂量他达拉非组59.1±9.4 m(vs 安慰剂 p=0.538)。
  • 他达拉非对次要结局(North Star Ambulatory Assessment和计时功能测试)无影响。
  • 在>10岁男孩中,低剂量他达拉非组PUL总分和肩部子评分下降较安慰剂组少。
  • 不良事件与他达拉非已知安全性及DMD疾病状态一致。

关键数值与推荐

  • 主要疗效指标为48周时6分钟步行距离(6MWD)。
  • 次要疗效指标包括North Star Ambulatory Assessment和计时功能测试。
  • Performance of Upper Limb(PUL)为预设探索性结局。

临床怎么用

  • 不推荐他达拉非用于减缓7–14岁DMD男孩的步行能力下降。
  • >10岁DMD男孩上肢功能获益需进一步研究确认。

局限性

  • 上肢功能数据为探索性、假设生成性结果,需进一步研究确认。
  • 研究未评估7岁前启动他达拉非对步行能力下降的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To conduct a randomized trial to test the primary hypothesis that once-daily tadalafil, administered orally for 48 weeks, lessens the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD). METHODS: Three hundred thirty-one participants with DMD 7 to 14 years of age taking glucocorticoids were randomized to tadalafil 0.3 mg·kg-1·d-1, tadalafil 0.6 mg·kg-1·d-1, or placebo. The primary efficacy measure was 6-minute walk distance (6MWD) after 48 weeks. Secondary efficacy measures included North Star Ambulatory Assessment and timed function tests. Performance of Upper Limb (PUL) was a prespecified exploratory outcome. RESULTS: Tadalafil had no effect on the primary outcome: 48-week declines in 6MWD were 51.0 ± 9.3 m with placebo, 64.7 ± 9.8 m with low-dose tadalafil (p = 0.307 vs placebo), and 59.1 ± 9.4 m with high-dose tadalafil (p = 0.538 vs placebo). Tadalafil also had no effect on secondary outcomes. In boys >10 years of age, total PUL score and shoulder subscore declined less with low-dose tadalafil than placebo. Adverse events were consistent with the known safety profile of tadalafil and the DMD disease state. CONCLUSIONS: Tadalafil did not lessen the decline in ambulatory ability in boys with DMD. Further studies should be considered to confirm the hypothesis-generating upper limb data and to determine whether ambulatory decline can be slowed by initiation of tadalafil before 7 years of age. CLINICALTRIALSGOV IDENTIFIER: NCT01865084. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that tadalafil does not slow ambulatory decline in 7- to 14-year-old boys with Duchenne muscular dystrophy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Victor RG, Sweeney HL, Finkel R, et al. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology. 2017. PMID: 28972192. doi:10.1212/WNL.0000000000004570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。